

REMARKS

Claims 1-28, 60, and 62-73 are pending.

Claims 1-9, 15-16, 24-28, 60, 62-64, 66 and 69-73 are allowed. Applicant appreciates the indication of the allowed claims in the Office Action.

Claims 10-14, 17-23, 65, 67 and 68 are objected in the Office Action. Applicant has canceled Claims 10-14, 17-23, 65, 67 and 68, without prejudice.

Claim Objections

Claim 10 is objected to under 37 C.F.R. 1.75 as being a substantial duplicate of claim 1. The Office Action states that the only component of the medicament of claim 10 is the peptide, its amide or ester, or salts thereof of claim 1.

Applicant respectfully traverses. However, solely for the purpose of advancing prosecution, Applicant has cancelled claim 10 without prejudice, rendering its rejection moot.

Claim 11 is objected to under 37 CFR 1.75 as being a substantial duplicate of claim 6. The Office Action states that the only component of the medicament of claim 11 is the peptide, its amide or ester, or salts thereof of claim 6.

Applicant respectfully traverses. However, solely for the purpose of advancing prosecution, Applicant has cancelled claim 11 without prejudice, rendering its rejection moot.

Claim 12 is objected to under 37 CFR 1.75 as being a substantial duplicate of claim 10, 11 and 65. The Office Action states that the only component of the medicament of claim 12 is the peptide, its amide or ester, or salts thereof of claim 10, 11, or 65.

Applicant respectfully traverses. However, solely for the purpose of advancing prosecution, Applicant has cancelled claim 12 without prejudice, rendering its rejection moot.

Claim 13 is objected to under 37 CFR 1.75 as being a substantial duplicate of claim 10, 11 and 65. The Office Action states that the only component of the medicament of claim 13 is the peptide, its amide or ester, or salts thereof of claim 10, 11, or 65.

Applicant respectfully traverses. However, solely for the purpose of advancing prosecution, Applicant has cancelled claim 13 without prejudice, rendering its rejection moot.

Claim 14 is objected to under 37 CFR 1.75 as being a substantial duplicate of claim 10, 11 and 65. The Office Action states that the only component of the medicament of claim 14 is the peptide, its amide or ester, or salts thereof of claim 10, 11, or 65.

Applicant respectfully traverses. However, solely for the purpose of advancing prosecution, Applicant has cancelled claim 14 without prejudice, rendering its rejection moot.

Claim 17 is objected to under 37 CFR 1.75 as being a substantial duplicate of claim 15. The Office Action states that the only component of the diagnostic agent of claim 17 is the antibody of claim 15.

Applicant respectfully traverses. However, solely for the purpose of advancing prosecution, Applicant has cancelled claim 17 without prejudice, rendering its rejection moot.

Claim 18 is objected to under 37 CFR 1.75 as being a substantial duplicate of claim 16. The Office Action states that the only component of the diagnostic agent of claim 18 is the antibody of claim 16.

Applicant respectfully traverses. However, solely for the purpose of advancing prosecution, Applicant has cancelled claim 18 without prejudice, rendering its rejection moot.

Claim 19 is objected to under 37 CFR 1.75 as being a substantial duplicate of claim 16, 18 or 67. The Office Action indicates the only component of the diagnostic agent of claim 19 is the antibody of claim 16, 18 or 67.

Applicant respectfully traverses. However, solely for the purpose of advancing prosecution, Applicant has cancelled claim 19 without prejudice, rendering its rejection moot.

Claim 20 is objected to under 37 CFR 1.75 as being a substantial duplicate of claim 15. The Office Action indicates the only component of the medicament of claim 20 is the antibody of claim 15.

Applicant respectfully traverses. However, solely for the purpose of advancing prosecution, Applicant has cancelled claim 20 without prejudice, rendering its rejection moot.

Claim 21 is objected to under 37 CFR 1.75 as being a substantial duplicate of claim 16. The Office Action indicates the only component of the medicament of claim 21 is the antibody of claim 16.

Applicant respectfully traverses. However, solely for the purpose of advancing prosecution, Applicant has cancelled claim 21 without prejudice, rendering its rejection moot.

Claim 22 is objected to under 37 CFR 1.75 as being a substantial duplicate of claim 20, 21 or 68. The Office Action indicates the only component of the medicament of claim 22 is the antibody of claim 20, 21 or 68.

Applicant respectfully traverses. However, solely for the purpose of advancing prosecution, Applicant has cancelled claim 22 without prejudice, rendering its rejection moot.

Claim 23 is objected to under 37 CFR 1.75 as being a substantial duplicate of claim 20, 21 or 68. The Office Action indicates the only component of the medicament of claim 23 is the antibody of claim 20, 21 or 68.

Applicant respectfully traverses. However, solely for the purpose of advancing prosecution, Applicant has cancelled claim 23 without prejudice, rendering its rejection moot.

Claim 65 is objected to under 37 CFR 1.75 as being a substantial duplicate of claim 62. The Office Action indicates the only component of the medicament of claim 65 is the antibody of claim 62.

Applicant respectfully traverses. However, solely for the purpose of advancing prosecution, Applicant has cancelled claim 65 without prejudice, rendering its rejection moot.

Claim 67 is objected to under 37 CFR 1.75 as being a substantial duplicate of claim 66. The Office Action indicates the only component of the diagnostic agent of claim 67 is the antibody of claim 66.

Applicant respectfully traverses. However, solely for the purpose of advancing prosecution, Applicant has cancelled claim 67 without prejudice, rendering its rejection moot.

Claim 68 is objected to under 37 CFR 1.75 as being a substantial duplicate of claim 66. The Office Action indicates the only component of the medicament of claim 68 is the antibody of claim 66.

Applicant respectfully traverses. However, solely for the purpose of advancing prosecution, Applicant has cancelled claim 68 without prejudice, rendering its rejection moot.

Conclusion

Applicant submits that all claims are allowable as written and respectfully request early favorable action by the Examiner. If the Examiner believes that a telephone conversation with Applicant's attorney/agent would expedite prosecution of this application, the Examiner is cordially invited to call the undersigned attorney/agent of record.

Respectfully submitted,

Date: January 22, 2010

/Amy DeCloux/
Name: Amy DeCloux,
Registration No.: 54,849
Name: David Conlin
Registration No.: 27,026
Customer No.: 21874
Edwards Angell Palmer & Dodge
LLP
P.O. Box 55874
Boston, MA 02205
Tel: 617-239-0100